Review Timeline | CrossMark Policy | ClinMed Features
logo
International Archives of
Urology and Complications ISSN: 2469-5742

Citation

Chraïbi M, Barqui M (2019) Small Cell Neuroendocrine Carcinoma of the Urinary Bladder: Rare Entity Associated to Poor Prognosis. Int Arch Urol Complic 5:055. doi.org/10.23937/2469-5742/1510055

Copyright

© 2019 Chraïbi M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

CASE REPORT | OPEN ACCESS DOI: 10.23937/2469-5742/1510055

Small Cell Neuroendocrine Carcinoma of the Urinary Bladder: Rare Entity Associated to Poor Prognosis

M Chraïbi1 and M Barqui2

1Pathology Department, Centre Hospitalo-Universitaire Mohammed VI Marrakech, Oujda, Morocco

2Urology Department, Centre Hospitalo-Universitaire Mohammed VI Marrakech, Oujda, Morocco

Abstract

Neuroendocrine Small cell Carcinoma (SCC) of the urinary bladder is a rare tumor. Pure Small Cell Carcinoma is uncounted from 0.5 to 1% of all primitive urinary tumors. The diagnosis is based on transurethral resection. The old age, and smoking are putative risk factors. A genetic predisposition is unknown.

Pure SCC of the bladder display metastasis and lymph nodes. Viscera and vertebral bones are the most common sites of the metastasis. Painless gross hematuria is the most common clinical feature. The prognosis is very poor. The overall survival rate at five years, in advanced stages does not exceed 8%.

SCC of the urinary bladder can be treated with local resection of the tumor or radical cystectomy with neoadjuvant or adjuvant chemotherapy. Radiation therapy is used as an alternative to radical cystectomy or as a palliative measure.